Unjha Formulations Limited (BOM:531762)
20.83
-0.37 (-1.75%)
At close: Jan 21, 2026
Unjha Formulations Revenue
Unjha Formulations had revenue of 43.47M INR in the quarter ending September 30, 2025, with 14.21% growth. This brings the company's revenue in the last twelve months to 141.50M, down -20.20% year-over-year. In the fiscal year ending March 31, 2025, Unjha Formulations had annual revenue of 139.30M, down -24.69%.
Revenue (ttm)
141.50M
Revenue Growth
-20.20%
P/S Ratio
0.68
Revenue / Employee
10.11M
Employees
14
Market Cap
96.24M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 139.30M | -45.67M | -24.69% |
| Mar 31, 2024 | 184.96M | 53.42M | 40.61% |
| Mar 31, 2023 | 131.54M | -10.24M | -7.22% |
| Mar 31, 2022 | 141.77M | 42.16M | 42.32% |
| Mar 31, 2021 | 99.62M | -8.50M | -7.86% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vivanza Biosciences | 663.49M |
| Sunrest Lifescience | 520.34M |
| Cian Healthcare | 232.80M |
| Beryl Drugs | 191.97M |
| Decipher Labs | 176.11M |
| Norris Medicines | 72.84M |
| Colinz Laboratories | 58.72M |
| Ganga Pharmaceuticals | 26.93M |